公开(公告)号：US20090226450A1

公开(公告)日：2009-09-10

申请号：US12386856

申请日：2009-04-23

申请人： Martin R. Hodge ,  Clare M. Lloyd ,  Nadine S. Weich ,  Jose M. Lora ,  David White ,  Maria A. Glucksmann ,  Keith E. Robison ,  Inmaculada Silos-Santiago ,  Andrew D.J. Goodearl ,  Rory A.J. Curtis

发明人： Martin R. Hodge ,  Clare M. Lloyd ,  Nadine S. Weich ,  Jose M. Lora ,  David White ,  Maria A. Glucksmann ,  Keith E. Robison ,  Inmaculada Silos-Santiago ,  Andrew D.J. Goodearl ,  Rory A.J. Curtis

IPC分类号： A61K39/395 ,  C12N15/11 ,  C12N5/00 ,  C07K14/00 ,  C07K16/18 ,  C12P21/02 ,  G01N33/566 ,  G01N33/53 ,  C12Q1/68 ,  A61K38/02 ,  A61K38/16 ,  A61K31/7088

CPC分类号： C07K14/47 ,  C07K16/286 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/726 ,  G01N2500/04 ,  G01N2800/122 ,  G01N2800/24

摘要： The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子，命名为15571,2465,14266,2882,52871,8203或16852核酸分子。 本发明还提供反义核酸分子，含有15571,2465,14266,2882,52871,8203或16852核酸分子的重组表达载体，已经引入表达载体的宿主细胞，以及非人类转基因动物，其中15571， 2465,14266,2882,52871,8203或16852基因已被引入或破坏。 本发明还进一步提供了分离的15571,2465,14266,2882,52871,8203或16852蛋白，融合蛋白，抗原肽和抗15571,2465,14266,2882,52871,8203或16852抗体。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US20110171205A1

公开(公告)日：2011-07-14

申请号：US13012890

申请日：2011-01-25

申请人： Martin R. Hodge ,  Clare M. Lloyd ,  Nadine S. Weich ,  Jose M. Lora ,  David White ,  Maria A. Glucksmann ,  Keith E. Robison ,  Inmaculada Silos-Santiago ,  Andrew D.J. Goodearl ,  Rory A.J. Curtis

发明人： Martin R. Hodge ,  Clare M. Lloyd ,  Nadine S. Weich ,  Jose M. Lora ,  David White ,  Maria A. Glucksmann ,  Keith E. Robison ,  Inmaculada Silos-Santiago ,  Andrew D.J. Goodearl ,  Rory A.J. Curtis

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12N5/00 ,  C07K14/00 ,  C07K16/18 ,  C12P21/02 ,  C12Q1/68 ,  G01N33/53 ,  A61K38/17 ,  A61K31/7088 ,  C12N15/11 ,  C12N1/21 ,  A61P25/00 ,  A61P19/02 ,  A61P25/28 ,  A61P25/16 ,  A61P25/18 ,  A61P9/00 ,  A61P9/04 ,  A61P35/00 ,  A61P3/10 ,  A61P15/02

CPC分类号： C07K14/47 ,  C07K16/286 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/726 ,  G01N2500/04 ,  G01N2800/122 ,  G01N2800/24

摘要： The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子，命名为15571,2465,14266,2882,52871,8203或16852核酸分子。 本发明还提供反义核酸分子，含有15571,2465,14266,2882,52871,8203或16852核酸分子的重组表达载体，已经引入表达载体的宿主细胞，以及非人类转基因动物，其中15571， 2465,14266,2882,52871,8203或16852基因已被引入或破坏。 本发明还进一步提供了分离的15571,2465,14266,2882,52871,8203或16852蛋白，融合蛋白，抗原肽和抗15571,2465,14266,2882,52871,8203或16852抗体。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US20090041752A1

公开(公告)日：2009-02-12

申请号：US11888354

申请日：2007-07-31

申请人： Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

发明人： Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

IPC分类号： A61K39/395 ,  A61K38/00 ,  A61P9/00

CPC分类号： C07K14/47

摘要： The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

摘要翻译： 本发明涉及用于治疗和诊断免疫疾病，特别是T辅助淋巴细胞相关病症的方法和组合物，还涉及治疗肥大细胞相关过程和病症，缺血性疾病和损伤，包括缺血性肾病和损伤 。 例如，识别在T辅助细胞（TH）细胞和TH细胞亚群内部和之间差异表达的基因，其包括但不限于TH0，TH1和TH2细胞亚群。 基因也通过其基因产物与涉及TH细胞和TH细胞亚群的分化，维持和效应子功能的基因产物相互作用的能力进行鉴定。 所鉴定的基因可以诊断使用或作为治疗干预的靶标。 在这方面，本发明提供了用于鉴定和治疗性使用化合物作为免疫疾病，特别是TH细胞亚群相关病症治疗的方法。 另外，提供了用于TH细胞亚群相关病症的诊断评估和预后的方法，用于鉴定表现出对这些病症倾向的受试者，用于监测接受临床评估治疗这种病症的患者，以及用于监测 化合物用于临床试验。 还提供了使用本发明的基因，基因产物和抗体治疗与肥大细胞相关过程或病症相关的症状以及缺血性疾病和损伤的方法。

公开(公告)号：US20120171204A1

公开(公告)日：2012-07-05

申请号：US13166982

申请日：2011-06-23

申请人： Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

发明人： Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

IPC分类号： A61K39/395 ,  A61P11/06 ,  A61P37/08 ,  A61P27/02 ,  G01N33/53 ,  A61P31/08 ,  C07K19/00 ,  C12Q1/68 ,  G01N21/64 ,  A61P37/00 ,  A61P33/02

CPC分类号： C07K14/47

摘要： The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

摘要翻译： 本发明涉及用于治疗和诊断免疫疾病，特别是T辅助淋巴细胞相关病症的方法和组合物，还涉及治疗肥大细胞相关过程和病症，缺血性疾病和损伤，包括缺血性肾病和损伤 。 例如，识别在T辅助细胞（TH）细胞和TH细胞亚群内部和之间差异表达的基因，其包括但不限于TH0，TH1和TH2细胞亚群。 基因也通过其基因产物与涉及TH细胞和TH细胞亚群的分化，维持和效应子功能的基因产物相互作用的能力进行鉴定。 所鉴定的基因可以诊断使用或作为治疗干预的靶标。 在这方面，本发明提供了用于鉴定和治疗性使用化合物作为免疫疾病，特别是TH细胞亚群相关病症治疗的方法。 另外，提供了用于TH细胞亚群相关病症的诊断评估和预后的方法，用于鉴定表现出对这些病症倾向的受试者，用于监测接受临床评估治疗这种病症的患者，以及用于监测 化合物用于临床试验。 还提供了使用本发明的基因，基因产物和抗体治疗与肥大细胞相关过程或病症相关的症状以及缺血性疾病和损伤的方法。

公开(公告)号：US20110123548A1

公开(公告)日：2011-05-26

申请号：US12729438

申请日：2010-03-23

申请人： Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

发明人： Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

IPC分类号： A61K39/395 ,  A61K38/17 ,  A61K48/00 ,  A61P9/10 ,  A61P13/12

CPC分类号： C07K14/47

摘要： The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

摘要翻译： 本发明涉及用于治疗和诊断免疫疾病，特别是T辅助淋巴细胞相关病症的方法和组合物，还涉及治疗肥大细胞相关过程和病症，缺血性疾病和损伤，包括缺血性肾病和损伤 。 例如，识别在T辅助细胞（TH）细胞和TH细胞亚群内部和之间差异表达的基因，其包括但不限于TH0，TH1和TH2细胞亚群。 基因也通过其基因产物与涉及TH细胞和TH细胞亚群的分化，维持和效应子功能的基因产物相互作用的能力进行鉴定。 所鉴定的基因可以诊断使用或作为治疗干预的靶标。 在这方面，本发明提供了用于鉴定和治疗性使用化合物作为免疫疾病，特别是TH细胞亚群相关病症治疗的方法。 另外，提供了用于TH细胞亚群相关病症的诊断评估和预后的方法，用于鉴定表现出对这些病症倾向的受试者，用于监测接受临床评估治疗这种病症的患者，以及用于监测 化合物用于临床试验。 还提供了使用本发明的基因，基因产物和抗体治疗与肥大细胞相关过程或病症相关的症状以及缺血性疾病和损伤的方法。